By Connor Hart
Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook.
The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million.
Shares fell 1.6%, to $6.03, in after-hours trading.
It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25.
Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 08, 2025 16:43 ET (21:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.